Compressing drug development timelines in oncology using phase '0' trials

Nature Reviews Cancer

Volumn 7, Issue 2, 2007, Pages 131-139

  Kummar, Shivaani ^b   Kinders, Robert ^a   Rubinstein, Larry ^a   Parchment, Ralph E ^a   Murgo, Anthony J ^a   Collins, Jerry ^a   Pickeral, Oxana ^a   Low, Jennifer ^a   Steinberg, Seth M ^b   Gutierrez, Martin ^b   Yang, Sherry ^a   Helman, Lee ^b   Wiltrout, Robert ^b   Tomaszewski, Joseph E ^a   Doroshow, James H ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MATRIX METALLOPROTEINASE INHIBITOR; NEW DRUG; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RADIOPHARMACEUTICAL AGENT;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD SAMPLING; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL VIABILITY; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CYTOTOXICITY; DATA ANALYSIS; DNA DAMAGE; DNA REPAIR; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXPLORATORY RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; IC 50; INFORMED CONSENT; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; PATIENT SELECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TUMOR BIOPSY; TUMOR CELL; UNITED STATES; WHOLE BODY IMAGING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; ETHICS, MEDICAL; HUMANS;

EID: 33846504444     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc2066     Document Type: Review

References (21)

1. US Food and Drug Administration. Guidance for Industry, Investigators, and Reviewers. US Food and Drug Administration [online], http://www.fda.gov/ cder/guidance/7086fnl.pdf (2006).
2. Kola, I., Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004).
3. Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431 (2001).
4. Olson, H., Betton, G., Robinson D. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67 (2000).
5. Tomaszewski, J. E., Smith, A. C., Covey, J. M., Donohue, S. J., Rhie, J. K. & Schweikart, K. M. in Anti-Cancer Drug Design (ed. Baguley, B. C.) Chpt 17, 301-328 (San Diego, Academic Press, 2001).
6. Tomaszewski, J. E., Doroshow, J. H. in Molecular Targets in Oncology (ed. Antman, K.) (Humana Press, Totowa, USA, in the press).
7. Fox, E., Curt, G. A. & Balis, F. M. Clinical trial design for target-based therapy. Oncologist. 7, 401-409 (2002).
8. Millar, A. W., Lynch, K. P. Rethinking clinical trials for cytostatic drugs. Nature Rev. Cancer. 3, 540-545 (2003).
9. Rothenberg, M. L., Carbone, D. P. & Johnson, D. H. Improving the evaluation of new cancer treatments: challenges and opportunities. Nature Rev. Cancer. 3, 303-309 (2003).
10. Kummar, S., Gutierrez, M. E., Doroshow, J. H. & Murgo, A. J. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br. J. Clin. Pharmacol. 62, 15-26 (2006).
11. Workman, P. et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J. Natl Cancer Inst. 98, 580-598 (2006).
12. Parulekar, W. R., Eisenhauer, E. A. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J. Natl. Cancer Inst. 96, 990-997 (2004).
13. Bartlett, J. M. Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy. Am. J. Pharmacogenomics 5, 303-315 (2005).
14. Lehmann, F., Lacombe, D., Therasse, P., Eggermont A. M. M. Integration of translational research in the european organization for research and treatment of cancer research (EORTC) clinical trial cooperative group mechanisms. J. Transl. Med. 1, 2 (2003).
15. Hidalgo, M., and Eckhardt, S. G. Matrix metalloproteinase inhibitors: how can we optimize their development? Ann. Oncol. 12, 285-287 (2001).
16. Moore, M. J. et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21, 3296-3302 (2003).
17. Van Den Bossche, B., Van de Wiele, C. Receptor imaging in oncology by means of nuclear medicine: current status. J. Clin. Oncol. 22, 3593-3607 (2004).
18. Sun, H. et al. Imaging the pharmacokinetics of [F-18]FAU in patients with tumors: PET studies. Cancer Chemother. Pharmacol. 57, 343-348 (2006).
19. Liu, G. et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J. Clin. Oncol. 23, 5464-5473 (2005).
20. Collins, J. M. Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development? J. Clin. Oncol. 23, 5417-5419 (2005).
21. Collins, J. M., Grieshaber, C. K. & Chabner, B. A. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Natl. Cancer Inst. 82, 1321-1326 (1990).